Amyris, Inc. (NASDAQ: AMRS) announced today that it has signed definitive agreements with Glycotech, Inc. and Salisbury Partners, LLC for Glycotech to provide chemical processing at Salisbury's Leland, NC facility to convert Amyris's Biofene?, or renewable farnesene, into finished products for a wide range of applications. The parties expect that Amyris's No Compromise® squalane will be the first Amyris product processed for commercial sale in the facility. The facility can also provide finishing services for other Amyris renewable products, including industrial lubricants, polymers and transportation fuels. All products will be owned and distributed solely by Amyris.

This agreement with Glycotech complements Amyris's existing production arrangements and provides Amyris with integrated capability from feedstock processing to the final product production process. Amyris expects that by controlling the final production step through the Glycotech relationship, it will be in a position to realize the economic benefits of expanded supply chain integration. Amyris has entered into agreements for the production of farnesene at a facility of Biomin GMBH located in Piracicaba, Brazil, and at a facility of Tate & Lyle located in Decatur, IL.

?We are excited to access this facility to perform our own chemical processing of farnesene into our target 2011 end products of squalane and lubricant,? said John Melo, CEO of Amyris. ?In addition, we can expand these operations to grow beyond our 2011 needs to support growth in several of our vertical markets.?

About Amyris

Amyris is building an integrated renewable products company by applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. Amyris Brasil S.A., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil, including SMA Indústria Química S.A., its joint venture with São Martinho. In addition, Amyris is building fuels distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. More information about Amyris and its subsidiaries is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding our expectations for the relationship with Glycotech, control of final production step and ability to realize economic benefits of supply chain integration, 2011 sales and commercialization and finishing of our products) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays in production and commercialization of products and other risks detailed in the ?Risk Factors? section of Amyris's final prospectus for its initial public offering, as filed on September 28, 2010 pursuant to Rule 424(b) under the Securities Act of 1933, and its quarterly report on Form 10-Q filed on November 10, 2010. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

Amyris, Inc.
Erin Kinsella, 510-597-4713
pr@amyris.com